ADGI

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Steven CohenPoint72 $-22.3M ExitQ4 2025 $22M -- --
Ken GriffinCitadel Advisors $-162.9K ExitQ4 2025 $163k -- --
Jefferies GroupInvestor $-101.5K ExitQ4 2025 $102k -- --
Ken GriffinCitadel Advisors $-173.8K ExitQ2 2025 $174k -- --
Stanley DruckenmillerDuquesne Family Office $-346 ExitQ2 2025 $346 -- --
Ken GriffinCitadel Advisors $142.2K AddQ1 2025 $142k -- --

Trade ADGI

About Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.

IPO Date: Aug 6, 2021

Market Data

Open: $4.62
High: $4.74
Low: $4.40
Volume: 535K

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsMay 14

actual -0.13